Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold

Radiotherapy and immunotherapy are most effective as cancer therapies in the setting of low-volume disease. Although initial studies of radio-immunotherapy in patients with metastatic cancer have not confirmed the efficacy of this approach, the role of radio-immunotherapy in patients with limited me...

Descripción completa

Detalles Bibliográficos
Autores principales: Turchan, William Tyler, Pitroda, Sean P., Weichselbaum, Ralph R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431248/
https://www.ncbi.nlm.nih.gov/pubmed/34502479
http://dx.doi.org/10.3390/ijms22179573
_version_ 1783750892358467584
author Turchan, William Tyler
Pitroda, Sean P.
Weichselbaum, Ralph R.
author_facet Turchan, William Tyler
Pitroda, Sean P.
Weichselbaum, Ralph R.
author_sort Turchan, William Tyler
collection PubMed
description Radiotherapy and immunotherapy are most effective as cancer therapies in the setting of low-volume disease. Although initial studies of radio-immunotherapy in patients with metastatic cancer have not confirmed the efficacy of this approach, the role of radio-immunotherapy in patients with limited metastatic burden is unclear. We propose that further investigation of radio-immunotherapy in metastatic patients should focus upon patients with oligometastatic disease.
format Online
Article
Text
id pubmed-8431248
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84312482021-09-11 Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold Turchan, William Tyler Pitroda, Sean P. Weichselbaum, Ralph R. Int J Mol Sci Review Radiotherapy and immunotherapy are most effective as cancer therapies in the setting of low-volume disease. Although initial studies of radio-immunotherapy in patients with metastatic cancer have not confirmed the efficacy of this approach, the role of radio-immunotherapy in patients with limited metastatic burden is unclear. We propose that further investigation of radio-immunotherapy in metastatic patients should focus upon patients with oligometastatic disease. MDPI 2021-09-03 /pmc/articles/PMC8431248/ /pubmed/34502479 http://dx.doi.org/10.3390/ijms22179573 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Turchan, William Tyler
Pitroda, Sean P.
Weichselbaum, Ralph R.
Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold
title Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold
title_full Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold
title_fullStr Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold
title_full_unstemmed Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold
title_short Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold
title_sort treatment of cancer with radio-immunotherapy: what we currently know and what the future may hold
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431248/
https://www.ncbi.nlm.nih.gov/pubmed/34502479
http://dx.doi.org/10.3390/ijms22179573
work_keys_str_mv AT turchanwilliamtyler treatmentofcancerwithradioimmunotherapywhatwecurrentlyknowandwhatthefuturemayhold
AT pitrodaseanp treatmentofcancerwithradioimmunotherapywhatwecurrentlyknowandwhatthefuturemayhold
AT weichselbaumralphr treatmentofcancerwithradioimmunotherapywhatwecurrentlyknowandwhatthefuturemayhold

Ejemplares similares